New editions: Anti-HIV drugs booklet & chart

Amelia Jones
Published: 05 June 2018

New editions of our Anti-HIV drugs booklet and Antiretroviral drugs chart are now available online and in print through our patient information scheme.

What’s in these resources?

The Anti-HIV drugs booklet is a starting point for anyone who wants to find out about treatment for HIV. It includes information on all the antiretroviral drugs that have been licensed in the UK or European Union and are recommended for prescription by the British HIV Association (BHIVA).

The Antiretroviral drugs chart is a one-page, full-colour reference guide, listing all the anti-HIV drugs licensed for use in the European Union.

The booklet and chart include information on drug formulations, approved dosages, side-effects and food restrictions.

Anti-HIV drugs and the Antiretroviral drugs chart have both been reviewed by a panel of medical experts to ensure they reflect current treatment guidelines. We have removed older drugs that are no longer in common use, added any new drugs, and included information on generic versions of drugs.

The booklet includes sections on:

NAM’s Patient Information Subscription Scheme

UK-based HIV and GUM clinics can order copies of Anti-HIV drugs and the Antiretroviral drugs chart, as well as all our other booklets and leaflets in our series The basics, through our online portal as part of our patient information subscription scheme.

(Please note, the Anti-HIV drugs booklet comes with a copy of the drugs chart.)

To find out if your clinic is registered or for information on joining the scheme, please contact NAM at or call 020 7837 6988.

Thank you

Thank you to the people living with HIV and members of our medical review panel for their assistance in reviewing the Anti-HIV drugs booklet: Celesta Riddles, Directorate pharmacist – HIV services, Ealing Hospital; Chris Birch; Jeremy; Dr Rachael Jones, Lead clinician, West London Centre for Sexual Health, Chelsea and Westminster Healthcare NHS Foundation Trust; Rosy Weston, Senior lead pharmacist for sexual health and HIV, St Mary’s Hospital, Imperial College Healthcare NHS Trust; Shema Doshi, Principal pharmacist sexual health, Caldecot Centre, King’s College Hospital NHS Foundation Trust; Silma Shah, Highly specialist pharmacist – HIV/GUM, Chelsea and Westminster Healthcare NHS Foundation Trust; Susanna Gilmour-White, Specialist pharmacist, Caldecot Centre, King’s College Hospital NHS Foundation Trust; Dr Tristan Barber, Consultant physician, Chelsea and Westminster Hospital.

And all pharmaceutical companies that provided product information: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Sharp and Dohme and ViiV Healthcare.

Thanks also to Wandsworth Oasis for funding the development of this resource. Our funders have had no editorial control over the content.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.